Evidence map›Paper›PMID 31123927›Full record

ReviewInternational journal of hematology2019

Current and future perspectives on allogeneic transplantation using ex vivo expansion or manipulation of umbilical cord blood cells.

Ko K Maung, Mitchell E Horwitz

Abstract readReview
PubMed Publisher
In one paragraph

Review in International journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Tailored Cytokine Optimization forFrontiers in bioengineering and biotechnology · 2020
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ko K MaungHematology and Medical Oncology Fellow, Duke University School of Medicine, 2400 Pratt St. DUMC 3961, Durham, NC, 27710, USA. KoKo.Maung@duke.edu.ORCID http://orcid.org/0000-0002-0768-0331
Mitchell E HorwitzAdult Blood and Marrow Transplant Program, Duke University School of Medicine, 2400 Pratt St. DUMC 3961, Durham, NC, 27710, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In patients with hematologic malignancies, the outcome of umbilical cord blood transplantation has improved and is now comparable to that of matched unrelated donor transplantation. However, the limitation of using umbilical cord blood has been a delay in both hematopoietic and immunologic recovery. Strategies have been proposed to overcome these limitations. One strategy involves ex vivo expansion of the umbilical cord blood unit prior to transplantation. A second strategy involves exposure of the umbilical cord blood graft to compounds aimed at improving homing and engraftment following transplantation. Many of these strategies are now being tested in late phase multi-center clinical trials. If proven cost effective and efficacious, they may alter the landscape of donor options for allogeneic stem cell transplantation.

Indexed as

Clinical Trials as TopicCord Blood Stem Cell TransplantationFetal BloodHematologic NeoplasmsHumansTransplantation, HomologousExpansionHematopoietic progenitor cellHematopoietic recoveryManipulationStem cell transplantationUmbilical cord blood

Identifiers

PMID31123927

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.